Radiotherapy is the major treatment of non-small cell lung cancer (NSCLC). The
radioresistance and toxicity are the main obstacles that leading to therapeutic failure and …

Simple Summary PARP inhibitors (PARPi) have broad applicability as monotherapy in
tumors with HR defects. However, their combination with radiotherapy (RT) is less advanced …

Formerly hailed as “undruggable” proteins, transcription factors (TFs) are now under
investigation for targeted therapy. In cancer, this may alter, inter alia, immune evasion or …

Multiple myeloma (MM) is a hematologic cancer characterized by accumulation of malignant
plasma cells in the bone marrow. To date, no definitive cure exists for MM and resistance to …

Background To identify radio‐responsive genes and explore the biological function of
encoded proteins in non‐small cell lung cancer (NSCLC). Methods Radio‐responsive …

PARP was an enzyme found in the nucleus of eukaryotic cells that played a crucial role in
repairing damaged DNA. Recently, PARP inhibitors have demonstrated great potential in …

Rectal cancer accounts for the second highest cancer-related mortality, which is
predominant in Western civilizations. The treatment for rectal cancers includes surgery …

Abstract Background Prostate cancer (PCa) is a prevalent malignant disease affecting a
significant number of males globally. Elevated expression of the Bloom's syndrome protein …

Simple Summary Biliary tract cancers (BTCs) are a rare but deadly group of gastrointestinal
tumors that are often diagnosed in the advanced stages of disease. Despite large studies …

Objective Our study aimed to investigate the potential clinical utility of a poly (ADP‐ribose)
polymerase (PARP) inhibitor, veliparib (ABT‐888), as a radiosensitizer in the medication of …